Literature DB >> 3046813

Influence of posture on hepatic perfusion and the presystemic biotransformation of propranolol: simulation of the food effect.

M W Modi1, J M Hassett, D Lalka.   

Abstract

Several research groups have reported that the oral administration of propranolol with protein-rich food leads to a marked increase (mean + 60%) in the area under the drug plasma concentration-time curve (AUC oral) of this highly metabolized and well-absorbed drug. It has been postulated that this "food effect" is caused at least in part by a transient increase in hepatic blood flow (QH) with its associated decrease in first-pass metabolism (hepatic extraction is a monotonic decreasing function of QH). A randomized crossover study using postural manipulations to produce changes in QH of the magnitude observed after food consumption (20% to 50%) was performed in an attempt to isolate the contribution of transient changes in QH to the food effect phenomenon. A solution of 80 mg propranolol HCl was taken orally and subjects were randomly assigned to postural manipulation protocols that should change QH such that AUC oral would be minimized (phase 1) or maximized (phase 2). Estimated QH (indocyanine green total body clearance from blood) was determined before and at three time points during each phase. It was observed that indocyanine green total body clearance during periods of standing was 15% to 40% below that observed during periods of seating (significant at p less than 0.05 for many of the appropriate comparisons). However, AUC oral for propranolol was not affected (mean +/- 1 SD; AUC phase 2/AUC phase 1+= 0.98 +/- 0.28) by these changes in QH, which are comparable to those encountered after food consumption.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046813     DOI: 10.1038/clpt.1988.149

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Mechanisms and variations in the food effect on propranolol bioavailability.

Authors:  H Liedholm; E Wåhlin-Boll; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Quantitative assessment of hepatic blood flow using intravenous indocyanine green.

Authors:  Joseph D Ma; Anne N Nafziger; William Mylott; David B Haughey; Mario L Rocci; Joseph S Bertino
Journal:  Eur J Clin Pharmacol       Date:  2008-07-02       Impact factor: 2.953

Review 3.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Effects of food on the pharmacokinetics of methylphenidate.

Authors:  K K Midha; G McKay; M J Rawson; E D Korchinski; J W Hubbard
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

5.  The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers.

Authors:  D L Wolf; J J Ferry; A E Hearron; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Influence of posture on pharmacokinetics.

Authors:  Christian Queckenberg; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-10-21       Impact factor: 2.953

Review 7.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

8.  The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers.

Authors:  D L Wolf; A E Hearron; C M Metzler; J J Ferry; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.